Rheumatoid Arthritis Treatment Market Trends

Growth Drivers  

• Healthcare quality improvement via EHR & PRO integration: AHRQ-supported projects like UCSF's use of NLP technology to extract patient-reported outcomes (PROs) from clinical notes. This has improved the quality of RA care, particularly for underserved populations. Thus, investing in digital approaches to capturing and acting on PRO data will support payers and providers trying to provide value-based reimbursement. AHRQ projects demonstrate how PRO dashboards promote shared decision-making and self-efficacy in RA care. Biopharma companies can establish performance-based pricing that links to real-world adherence and outcomes using EHR-integrated PRO systems.
• Patient pool trends & care disparities: RA impacts around 1.1 million Americans. This highlights the underserved demand. Targeted outreach and funding for community health programs can meet unmet demand and help to improve equity in the delivery of care. According to the Digital Healthcare Research Program at AHRQ, RISE registry data indicate that several quality improvement interventions positively improved adherence to RA activity measures. Manufacturers and technology partners provide support to healthcare systems through analytical support and training to improve performance metrics.

Historical Patient Growth for RA Treatment Users (2010–2020)

Synopsis: Feasible Expansion Models Reshaping the RA Treatment Market

New expansion models developing in the rheumatoid arthritis (RA) therapy space increasingly emphasize partnerships. These models suggest a future of growth based on scalable cost savings and expanded access. With governmental involvement increasing, the RA market is in a position that more inclusively facilitates sustainable growth that is driven by volume.

Statistical Revenue Feasibility Models

Challenges

• Prohibitively high treatment cost: Biologics can cost over USD 25700 per annum per patient in the US. The World Health Organization (WHO) cites that biosimilars are 59% lower. However, the high price of originators inhibits use. According to the WHO, out-of-pocket expenses are the largest financial barrier. Moreover, tender systems based on the lowest cost often led to supply shortages or discourage new entrants.
• Regulatory delays and price negotiations: Regulatory delays add time to the timeline for new RA treatments to reach the market. This ultimately slows the ability of the market to incorporate innovation. Longer timelines mean higher R&D costs for drug developers. This can deter investment in new RA therapeutics.